Dirk Behringer

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · The Lancet · 2019 · 2.6K citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 739 citations

Medicine, Oncology, Pharmacology +16

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

Stephen Chan, M. E. Scheulen, S. Johnston et al. · Journal of Clinical Oncology · 2005 · 468 citations · Full text

Medicine, Oncology, Pharmacology +16

Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial

Ulrich Dührsen, Stefan Müller, Bernd Hertenstein et al. · Journal of Clinical Oncology · 2018 · 251 citations · Full text

Medicine, Oncology, Chemotherapy +14

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia

Tristan M. Sissung, K. Mross, Seth M. Steinberg et al. · European Journal of Cancer · 2006 · 169 citations · Full text

Medicine, Genetics, Oncology +7